Antiglomerular basement membrane antibody type rapidly progressive glomerulonephritis with seizures: Two cases and literature review
12.01.22 FDA approves Wegovy for adolescents The FDA approved Wegovy to be used for weight loss in adolescents aged 12 or older
Endocrinology 150(6):26542659 Hjerpsted JB, Flint A, Brooks A, Axelsen MB, Kvist T, Blundell J (2018) Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity
Sleep apnea affects an estimated 2% to 5% of the US population
FIP produces significant immune dysregulation
placebo in adults with overweight or obesity without diabetes (STEP 3), mean body weight decreased 16.0% with semaglutide compared with 5.7% with placebo, both as adjunct to intensive behavioral therapy (ETD 10.3%